Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Nasser M Alorfi & Fahad S Alshehri. (2023) Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov. Journal of Multidisciplinary Healthcare 16, pages 2179-2187.
Read now
Read now
André J Scheen. (2023) Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Review of Clinical Pharmacology 16:11, pages 1053-1062.
Read now
Read now
Venkateshwaran Thamaraiselvan & Ravichandiran Velayutham. (2022) The putative binding site and SAR rationalization of small molecules against glucagon-like peptide-1 receptor using homology model and crystal structures: a comparative study. Journal of Biomolecular Structure and Dynamics 40:5, pages 2038-2052.
Read now
Read now
Heshma Alruwaili, Babak Dehestani & Carel W le Roux. (2021) Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology: Advances and Applications 13, pages 53-60.
Read now
Read now
Chen-Hsiu Lin, Li Shao, Yu-Mei Zhang, Yu-Ju Tu, Yuzhen Zhang, Brian Tomlinson, Paul Chan & Zhongmin Liu. (2020) An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy 21:3, pages 275-285.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opinion on Investigational Drugs 25:2, pages 145-158.
Read now
Read now
Ellen E Ladenheim. (2015) Liraglutide and obesity: a review of the data so far. Drug Design, Development and Therapy 9, pages 1867-1875.
Read now
Read now
Articles from other publishers (28)
Venelin Dimitrov Denchev & Teodora Svetoslavova Handjieva-Darlenska. (2023) Pharmacological methods for weight reduction and their connection with the human gut microbiota. Pharmacia 70:4, pages 1471-1477.
Crossref
Crossref
Jonathon H. Watanabe. (2023) Considerations on the Weight Loss-Associated Glucagon-like Peptide-1 Receptor Agonists for Older People. The Senior Care Pharmacist 38:12, pages 493-496.
Crossref
Crossref
Jing Xu, Shuang Wang, Han Wu, De Chen, Jing Han & Qisi Lin. (2023) Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity. Peptides 169, pages 171073.
Crossref
Crossref
Luge Wei, Lanqi Ji, Yulu Miao, Xu Han, Ying Li, Zhe Wang, Jiafeng Fu, Liuli Guo, Yuanyuan Su & Yanjun Zhang. (2023) Constipation in DM are associated with both poor glycemic control and diabetic complications: Current status and future directions. Biomedicine & Pharmacotherapy 165, pages 115202.
Crossref
Crossref
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, Kamel Metwally & Simona Cavalu. (2023) Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences 24:13, pages 10449.
Crossref
Crossref
Anandan Palani, Andrea R. NawrockiFederica Orvieto, Elisabetta Bianchi, Emanuela Mandić, Antonello Pessi, Chunhui Huang, Qiaolin Deng, Nathalie ToussaintErika WalshVijay ReddyEric Ashley, Huaibing HeSheena MumickBrian HawesDonald MarshMark ErionRavi NargundPaul E. Carrington. (2022) Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes. ACS Medicinal Chemistry Letters 13:8, pages 1248-1254.
Crossref
Crossref
Claudio Ponticelli & Franco Citterio. (2022) Non-Immunologic Causes of Late Death-Censored Kidney Graft Failure: A Personalized Approach. Journal of Personalized Medicine 12:8, pages 1271.
Crossref
Crossref
Melena D. Bellin. (2022) Pancreatogenic Diabetes in Children With Recurrent Acute and Chronic Pancreatitis: Risks, Screening, and Treatment (Mini-Review). Frontiers in Pediatrics 10.
Crossref
Crossref
Sathish Sivaprakasam, Sabarish RamachandranMohd Omar Faruk SikderYangzom D. BhutiaMitchell W. WachtelVadivel Ganapathy. (2021)
α-Methyl-
l
-tryptophan as a weight-loss agent in multiple models of obesity in mice
. Biochemical Journal 478:7, pages 1347-1358.
Crossref
Crossref
Jenna Elizabeth Hunt, Jens Juul Holst, Palle Bekker Jeppesen & Hannelouise Kissow. (2021) GLP-1 and Intestinal Diseases. Biomedicines 9:4, pages 383.
Crossref
Crossref
Jie Cui, Anquan Shang, Weiwei Wang & Wei Chen. (2020) Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals. Life Sciences 260, pages 118339.
Crossref
Crossref
Martin Larsson, Maaret Castrén, Veronica Lindström, Mia Euler, Cesare Patrone, Nils Wahlgren & David Nathanson. (2019) Prehospital exenatide in hyperglycemic stroke—A randomized trial. Acta Neurologica Scandinavica 140:6, pages 443-448.
Crossref
Crossref
Mehran Mesgari-Abbasi, Solin Ghaderi, Monire Khordadmehr, Katayoon Nofouzi, Hossein Tayefi-Nasrabadi & Graham McIntyre. (2019)
Enteroprotective effect of
Tsukamurella inchonensis
on streptozotocin induced type 1 diabetic rats
. Turkish Journal of Biochemistry 44:5, pages 683-691.
Crossref
Crossref
A. Bonaventura, S. Carbone, D. L. Dixon, A. Abbate & F. Montecucco. (2019)
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on
SGLT
‐2 inhibitors and
GLP
‐1 receptor agonists
. Journal of Internal Medicine 286:1, pages 16-31.
Crossref
Crossref
A.R. Pinho, A. Fortuna, A. Falcão, A.C. Santos, R. Seiça, C. Estevens, F. Veiga & A.J. Ribeiro. (2019) Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. Journal of Pharmaceutical Analysis 9:3, pages 143-155.
Crossref
Crossref
Steve Peigneur & Jan Tytgat. (2018) Toxins in Drug Discovery and Pharmacology. Toxins 10:3, pages 126.
Crossref
Crossref
Marinko Marušić, Rosana Troskot Perić & Nikolina Tolj Karaula. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes
191
201
.
Alen Bišćanin. 2018. Gastrointestinal Complications of Diabetes. Gastrointestinal Complications of Diabetes
163
176
.
Blanca E. Ocampo-García, Clara L. Santos-Cuevas, Myrna A. Luna-Gutiérrez, Eleazar Ignacio-Alvarez, Martha Pedraza-López & Cesar Manzano-Mayoral. (2017) 99mTc-exendin(9-39)/octreotide. Nuclear Medicine Communications 38:11, pages 912-918.
Crossref
Crossref
Michael E. Trautmann, Luc Van Gaal, Jenny Han & Elise Hardy. (2017) Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. Journal of Diabetes and its Complications 31:9, pages 1415-1422.
Crossref
Crossref
D. Athauda & T. Foltynie. (2016) Insulin resistance and Parkinson’s disease: A new target for disease modification?. Progress in Neurobiology 145-146, pages 98-120.
Crossref
Crossref
Tat'jana Vladimirovna Saprina & Nailja Maratovna Fajzulina. (2016) Diabetes type 2 diabetes in the elderly – solved and unsolved questions. Diabetes mellitus 19:4, pages 322-330.
Crossref
Crossref
Abigail Maisey. (2016) A Practical Approach to Gastrointestinal Complications of Diabetes. Diabetes Therapy 7:3, pages 379-386.
Crossref
Crossref
Opeolu O. Ojo, Dinesh K. Srinivasan, Bosede O. Owolabi, Mary K. McGahon, R. Charlotte Moffett, Tim M. Curtis, J. Michael Conlon, Peter R. Flatt & Yasser H.A. Abdel-Wahab. (2016) Molecular mechanisms mediating the beneficial metabolic effects of [Arg4]tigerinin-1R in mice with diet-induced obesity and insulin resistance. Biological Chemistry 397:8, pages 753-764.
Crossref
Crossref
Midhat H. Abdulreda, Rayner Rodriguez-Diaz, Alejandro Caicedo & Per-Olof Berggren. (2016) Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model. Cell Metabolism 23:3, pages 541-546.
Crossref
Crossref
Sean M. Brady, Michael P. Kane & Robert S. Busch. (2016) GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis. AACE Clinical Case Reports 2:2, pages e82-e85.
Crossref
Crossref
Curtis TriplittCarolina Solis-Herrera. (2015) GLP-1 Receptor Agonists. The Diabetes Educator 41:1_suppl, pages 32S-46S.
Crossref
Crossref
Veronica Medina-García, Blanca E. Ocampo-García, Guillermina Ferro-Flores, Clara L. Santos-Cuevas, Liliana Aranda-Lara, Rocio García-Becerra, David Ordaz-Rosado & Laura Melendez-Alafort. (2015) A freeze-dried kit formulation for the preparation of Lys 27 ( 99m Tc-EDDA/HYNIC)-Exendin(9-39)/ 99m Tc-EDDA/HYNIC-Tyr 3 -Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42:12, pages 911-916.
Crossref
Crossref